Heart Failure Reviews

, Volume 17, Issue 4–5, pp 531–544 | Cite as

Prevention of heart failure in the elderly: when, where and how to begin?

  • Bodh I. JugduttEmail author


Significant growth in the elderly population (age ≥ 65 years) with heart failure (HF) has taken place in developed countries and is occurring in most developing countries. Projections from population studies in the United States, Europe and other developed countries suggest that this trend will very likely continue and tax healthcare systems worldwide. Prevention of HF in the elderly should be a healthcare priority. Preventive strategies are urgently needed to combat the rising burden of HF and related complications in elderly men and women of tomorrow. The strategies should address the aging continuum and the cumulative impact of lifelong exposure to cardiovascular (CV) risk factors and consider the associated pathobiology and pathophysiology of aging for optimal impact. Besides implementation of conventional primary and secondary prevention measures in young and older adults, more emphasis should be placed on education about the role of exposure to adverse CV risk factors from early childhood in the march to HF. More research is also needed to identify optimal HF therapies for different aging subgroups ranging from young adults to the elderly and very old based on understanding of pathobiology and pathophysiology.


Aging Heart failure Markers Telomere length Prevention strategies 



This work was supported in part by grant # IAP-99003 from the Canadian Institutes of Health Research, Ottawa, Ontario. We thank Catherine Jugdutt for assistance.

Conflict of interest



  1. 1.
    Centers for Disease Control and Prevention (2003) Public health and aging: trends in aging: United States and worldwide. MMRW Morb Mortal Wkly Rep 52:101–106. Available at: Accessed 18 Aug 2011
  2. 2.
    He W, Sengupta M, Velkoff VA, DeBarros KA (2005) 65+ in the United States: 2005. Current Population Reports, P23-209. Government Printing Office, Washington, DC. Available at: Accessed 18 Aug 2011
  3. 3.
    Kannel WB, Belanger AJ (1991) Epidemiology of heart failure. Am Heart J 121:951–957PubMedGoogle Scholar
  4. 4.
    Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:e46–e215PubMedGoogle Scholar
  5. 5.
    Hunt SA, Abraham WT, Chin MH et al (2009) 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation. Circulation 119:e391–e479PubMedGoogle Scholar
  6. 6.
    Johansen H, Strauss B, Arnold MO, Moe G, Liu P (2003) On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol 19:430–435PubMedGoogle Scholar
  7. 7.
    Arnold MO, Liu P, Demers C et al (2006) Canadian cardiovascular society consensus conference recommendations on heart failure 2006: diagnosis and treatment. Can J Cardiol 22:23–45PubMedGoogle Scholar
  8. 8.
    Jelani A, Jugdutt BI (2010) STEMI and heart failure in the elderly: role of adverse remodeling. Heart Fail Rev 15:513–521PubMedGoogle Scholar
  9. 9.
    Jugdutt BI (2010) Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail Rev 15:401–405PubMedGoogle Scholar
  10. 10.
    Jugdutt BI (2010) Heart failure in the elderly: advances and challenges. Expert Rev Cardiovasc Ther 8:695–715PubMedGoogle Scholar
  11. 11.
    Jugdutt BI (2011) Biology of aging and heart failure management. In: Proceedings of the international academy of cardiology 16th world congress on heart disease annual scientific sessions 2011. Medimond, Bologne, Italy (in press)Google Scholar
  12. 12.
    O’Connell JB (2000) The economic burden of heart failure. Clin Cardiol 23(Suppl III):6–103Google Scholar
  13. 13.
    Committee on the Future Health Care Workforce for Older Americans, Board of Health Care Services (2008) Retooling for an aging America: building the health care workforce. National Academies Press, Washington, DC. Available at: Accessed 18 Aug 2011
  14. 14.
    Stevenson LW (2011) Projecting heart failure into bankruptcy in 2012? Am Heart J 161:1007–1011PubMedGoogle Scholar
  15. 15.
    Lakatta EG, Gerstenblith G, Weisfeldt ML (1997) The aging heart: structure, function, and disease. In: Braunwald E (ed) Heart disease. Saunders, Philadelphia, pp 1687–1700Google Scholar
  16. 16.
    Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I. Circulation 107:139–146PubMedGoogle Scholar
  17. 17.
    Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II. Circulation 107:346–354PubMedGoogle Scholar
  18. 18.
    Lakatta EG, Wang M, Najjar SS (2009) Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am 93:583–604PubMedGoogle Scholar
  19. 19.
    Lloyd-Jones DM, Larson MG, Leip EP et al (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106:3068–3072PubMedGoogle Scholar
  20. 20.
    Jugdutt BI (2010) Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging 5:403–416PubMedGoogle Scholar
  21. 21.
    Goldberg RJ, McCormick D, Gurwitz JH et al (1998) Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975–1995). Am J Cardiol 82:1311–1317PubMedGoogle Scholar
  22. 22.
    Yusuf S, Hawken S, Ounpuu S, for the INTERHEART Study Investigators et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952PubMedGoogle Scholar
  23. 23.
    Kannel WB (1990) Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol 15:206–211PubMedGoogle Scholar
  24. 24.
    Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III (1961) Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med 55:33–50PubMedGoogle Scholar
  25. 25.
    Kannel WB (2011) Sixty years of preventive cardiology: a Framingham perspective. Clin Cardiol 34:342–343PubMedGoogle Scholar
  26. 26.
    Lloyd-Jones DM, Larson MG, Beiser A, Levy D (1999) Lifetime risk of developing coronary artery disease. Lancet 353:89–92PubMedGoogle Scholar
  27. 27.
    Lloyd-Jones DM, Nam BH, D’Agostino RB Sr et al (2004) Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. A prospective study of parents and offspring. JAMA 291:2204–2211PubMedGoogle Scholar
  28. 28.
    Lloyd-Jones DM, Leip EP, Larson MG et al (2006) Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113:791–798PubMedGoogle Scholar
  29. 29.
    Terry DF, Pencina MJ, Vasan RS et al (2005) Cardiovascular risk factors predictive for survival and morbidity-free survival in the oldest-old Framingham Heart Study participants. J Am Geriatr Soc 53:1944–1950PubMedGoogle Scholar
  30. 30.
    Dawber TR, Moore FE Jr, Mann GV (1957) Coronary heart disease in the Framingham Study. Am J Public Health 47:4–24Google Scholar
  31. 31.
    Dawber TR, Kannel WB (1966) The Framingham Study: an epidemiological approach to coronary heart disease. Circulation 34:553–555PubMedGoogle Scholar
  32. 32.
    Grundy SM (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421 Google Scholar
  33. 33.
    Wilson PWF, D’Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMedGoogle Scholar
  34. 34.
    Smith SC, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113:2363–2372PubMedGoogle Scholar
  35. 35.
    D’Agostino RB, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 117:743–753PubMedGoogle Scholar
  36. 36.
    Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 297:611–619PubMedGoogle Scholar
  37. 37.
    DeFilippis AP, Blaha MJ, Ndumele CE et al (2011) The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 58:2076–2083PubMedGoogle Scholar
  38. 38.
    Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR (2008) C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds risk score for men. Circulation 118:2243–2251PubMedGoogle Scholar
  39. 39.
    Alberti G, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group (2005) The metabolic-syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedGoogle Scholar
  40. 40.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 352:1296–1305Google Scholar
  41. 41.
    Genest J, McPherson R, Frohlich J et al (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol 25:567–579PubMedGoogle Scholar
  42. 42.
    Nasir K, Michos ED, Rumberger JA et al (2004) Coronary artery calcification and family history of premature coronary heart disease. Sibling history is more strongly associated than parental history. Circulation 110:2150–2156PubMedGoogle Scholar
  43. 43.
    Mora S, Yanek LR, Moy TF, Fallin D, Becker LC, Becker DM (2005) Interaction of body mass index and Framingham risk score in predicting incident coronary disease in families. Circulation 111:1871–1876PubMedGoogle Scholar
  44. 44.
    Baigent C, Keech A, Kearney PM, for the Cholesterol Treatment Trialists’ (CTT) Collaborators et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366:1267–1278PubMedGoogle Scholar
  45. 45.
    Ridker PM, Danielson E, Fonseca FAH, for the JUPITER Study Group et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 359:2195–2207PubMedGoogle Scholar
  46. 46.
    Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE (2005) Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294:326–333PubMedGoogle Scholar
  47. 47.
    Wijeysundera HC, Machado M, Farahati F et al (2010) Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA 303:1841–1847PubMedGoogle Scholar
  48. 48.
    Zethelius B, Berglund L, Sundström J et al (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358:2107–2116PubMedGoogle Scholar
  49. 49.
    Melander O, Newton-Cheh C, Almgren P et al (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49–57PubMedGoogle Scholar
  50. 50.
    Daniels LB, Laughlin GA, Clopton P et al (2008) Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 52:450–459PubMedGoogle Scholar
  51. 51.
    deFilippi CR, Christenson RH, Gottdiener JS et al (2010) Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol 55:441–450PubMedGoogle Scholar
  52. 52.
    Januzzi JL Jr, Rehman S, Mohammed AA et al (2011) Use of amino-terminal pro-B natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58:1881–1889PubMedGoogle Scholar
  53. 53.
    Sundström J, Ingelsson E, Berglund L et al (2009) Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur Heart J 30:773–781PubMedGoogle Scholar
  54. 54.
    deFilippi CR, de Lemos JA, Christenson RH et al (2011) Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304:2494–2502Google Scholar
  55. 55.
    Shlipak MG, Fried LF, Cushman M et al (2005) Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293:1737–1745PubMedGoogle Scholar
  56. 56.
    Petretta M, Daniele S, Acampa W et al (2011) Prognostic value of coronary artery calcium score and coronary CT angiography in patients with intermediate risk of coronary artery disease. Int J Cardiovasc Imaging. doi: 10.1007/s10554-011-9948-5
  57. 57.
    van Velzen JE, de Graaf FR, Jukema JW et al (2011) Comparison of the relation between the calcium score and plaque characteristics in patients with acute coronary syndrome versus patients with stable coronary artery disease, assessed by computed tomography angiography and virtual histology intravascular ultrasound. Am J Cardiol 108:658–664PubMedGoogle Scholar
  58. 58.
    Kerut EK (2011) Coronary risk assessment and arterial age calculation using coronary artery calcium scoring and the Framingham risk score. Echocardiography 28:686–693PubMedGoogle Scholar
  59. 59.
    Güder G, Bauersachs J, Frantz S, Weismann D et al (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115:1754–1761PubMedGoogle Scholar
  60. 60.
    Kitzman DW, Little WC, Brubaker PH, Anderson RT et al (2002) Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288:2144–2150PubMedGoogle Scholar
  61. 61.
    Maisel AS, McCord J, Nowak RM et al (2003) Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the breathing not properly multinational study. J Am Coll Cardiol 41:2010–2017PubMedGoogle Scholar
  62. 62.
    Maisel AS, Hollander JE, Guss D et al (2004) Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44:1328–1333PubMedGoogle Scholar
  63. 63.
    Benedict CR, Weiner DH, Johnstone DE et al (1993) Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry. J Am Coll Cardiol 22(Suppl A):146A–153APubMedGoogle Scholar
  64. 64.
    Aronow WS, Fleg JL, Pepine CJ et al (2011) ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens 5:259–352PubMedGoogle Scholar
  65. 65.
    Alexander KP, Newby LK, Cannon CP et al (2007) Acute coronary care in the elderly, part I. Non-ST-segment-elevation acute coronary syndromes. A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115:2549–2569PubMedGoogle Scholar
  66. 66.
    Alexander KP, Newby LK, Armstrong PW et al (2007) American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115:2570–2589PubMedGoogle Scholar
  67. 67.
    Jessup M, Abraham WT, Casey DE et al (2009) Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 119:1977–2016PubMedGoogle Scholar
  68. 68.
    International Diabetes Federation (2006) The IDF consensus worldwide definition of the metabolic syndrome.
  69. 69.
    Ogden CL, Carroll MD, Curtin LR et al (2006) Prevalence of overweight and obesity in the United States: 1999–2004. JAMA 295:1549–1555PubMedGoogle Scholar
  70. 70.
    Narayan KM, Boyle JP, Thompson TJ et al (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290:1884–1890PubMedGoogle Scholar
  71. 71.
    Gupta AK, Dahlof B, Dobson J et al (2008) Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 31:982–988PubMedGoogle Scholar
  72. 72.
    Cooper-DeHoff R, Cohen JD, Bakris GL et al (2006) Predictions of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril study (INVEST). Am J Cardiol 98:890–894PubMedGoogle Scholar
  73. 73.
    Bertoni AG, Hundley WG, Massing MW et al (2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27:699–703PubMedGoogle Scholar
  74. 74.
    Yusuf S, Teo KK, for the ONTARGET Investigators et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559PubMedGoogle Scholar
  75. 75.
    Held C, Gerstein HC, Yusuf S et al (2007) Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 115:1371–1375PubMedGoogle Scholar
  76. 76.
    Brownlee M (2005) The pathobiology of diabetic complications. A unifying mechanism. Diabetes 54:1615–1625PubMedGoogle Scholar
  77. 77.
    Ceriello A (2005) Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes 54:1–7PubMedGoogle Scholar
  78. 78.
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedGoogle Scholar
  79. 79.
    Deedwania Kosiborod M, Barrett E et al (2008) Hyperglycemia and acute coronary syndrome. A scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, physical activity, and metabolism. Circulation 117:1610–1619Google Scholar
  80. 80.
    Kannel WB, Abbott RD, Savage DD, McNamara PM (1983) Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 106:389–396PubMedGoogle Scholar
  81. 81.
    Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM (1994) Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74:236–241PubMedGoogle Scholar
  82. 82.
    Dries DL, Exner DV, Gersh BJ et al (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of left ventricular dysfunction. J Am Coll Cardiol 32:695–703PubMedGoogle Scholar
  83. 83.
    Fuster V, Ryden LE, Cannon DS, for the Writing Committee Members et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257–e354PubMedGoogle Scholar
  84. 84.
    Friberg J, Scharling H, Gadsbøll N, Jensen GB (2003) Sex-specific increase in the prevalence of atrial fibrillation (the Copenhagen City Heart Study). Am J Cardiol 92:1419–1423PubMedGoogle Scholar
  85. 85.
    Ruo B, Capra AM, Jensvold NG et al (2004) Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the epidemiology, practice, outcomes, and costs of heart failure (EPOCH) study. J Am Coll Cardiol 43:429–435PubMedGoogle Scholar
  86. 86.
    Aronow WS, Banach M (2009) Atrial fibrillation: the new epidemic of the aging world. J Atr Fibrillation 1:337–361Google Scholar
  87. 87.
    Wattigney WA, Mensah GA, Croft JB (2003) Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108:711–716PubMedGoogle Scholar
  88. 88.
    Mozaffarian D, Furberg CD, Psaty BM et al (2008) Physical activity and incidence of atrial fibrillation in older adults: the Cardiovascular Health Study. Circulation 118:800–807PubMedGoogle Scholar
  89. 89.
    Curtis AB, Bersh BJ, Corley SD et al (2005) Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149:645–659PubMedGoogle Scholar
  90. 90.
    Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb? Mutat Res 256:271–282PubMedGoogle Scholar
  91. 91.
    Vaziri H, Dragowska W, Allsopp RC et al (1994) Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 91:9857–9860PubMedGoogle Scholar
  92. 92.
    Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611–622PubMedGoogle Scholar
  93. 93.
    Takubo K, Izumiyama-Shimomura N, Honma N et al (2002) Telomere lengths are characteristic in each human individual. Exp Gerontol 37:523–531PubMedGoogle Scholar
  94. 94.
    Slagboom PE, Droog S, Boomsma DI (1994) Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 55:876–882PubMedGoogle Scholar
  95. 95.
    Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458–460PubMedGoogle Scholar
  96. 96.
    Xu D, Neville R, Finkel T (2000) Homocysteine accelerates endothelial cell senescence. FEBS Lett 470:20–24PubMedGoogle Scholar
  97. 97.
    Demissie S, Levy D, Benjamin EJ et al (2006) Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 5:325–330PubMedGoogle Scholar
  98. 98.
    Bekaert S, De Meyer T, Rietzschel ER, on behalf of the Asklepios investigators et al (2007) Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell 6:639–647PubMedGoogle Scholar
  99. 99.
    Samani NJ, Boultby R, Butler R et al (2001) Telomere shortening in atherosclerosis. Lancet 358:472–473PubMedGoogle Scholar
  100. 100.
    Cawthon RM, Smith KR, O’Brien E et al (2003) Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361:393–395PubMedGoogle Scholar
  101. 101.
    Brouilette S, Singh RK, Thompson JR et al (2003) White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 23:842–846PubMedGoogle Scholar
  102. 102.
    Brouilette SW, Moore JS, McMahon AD, for the West of Scotland Coronary Prevention Study Group et al (2007) Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369:107–114PubMedGoogle Scholar
  103. 103.
    Fitzpatrick AL, Kronmal RA, Gardner JP et al (2007) Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 165:14–21PubMedGoogle Scholar
  104. 104.
    Benetos A, Gardner JP, Zureik M et al (2004) Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 43:182–185PubMedGoogle Scholar
  105. 105.
    van der Harst P, van der Steege G, de Boer RA et al (2007) Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 49:1459–1464PubMedGoogle Scholar
  106. 106.
    Collerton J, Martin-Ruiz C, Kenny A et al (2007) Telomere length is associated with left ventricular function in the oldest old: the Newcastle 85+ study. Eur Heart J 28:172–176PubMedGoogle Scholar
  107. 107.
    Jeanclos E, Krolewski A, Skurnick J et al (1998) Shortened telomere length in white blood cells of patients with IDDM. Diabetes 47:482–486PubMedGoogle Scholar
  108. 108.
    Sampson MJ, Winterbone MS, Hughes JC et al (2006) Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 29:283–289PubMedGoogle Scholar
  109. 109.
    Benetos A, Okuda K, Lajemi M et al (2001) Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 37:381–385PubMedGoogle Scholar
  110. 110.
    Valdes AM, Andrew T, Gardner JP et al (2005) Obesity, cigarette smoking, and telomere length in women. Lancet 366:662–664PubMedGoogle Scholar
  111. 111.
    Cherkas LF, Aviv A, Valdes AM et al (2006) The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging Cell 5:361–365PubMedGoogle Scholar
  112. 112.
    Zee RYL, Michaud SE, Germer S, Ridker PM (2009) Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta 403:139–141PubMedGoogle Scholar
  113. 113.
    Samani NJ, Harst PV (2008) Biological aging and cardiovascular disease. Heart 94:537–539PubMedGoogle Scholar
  114. 114.
    Kyo S, Takakura M, Kanaya T et al (1999) Estrogen activates telomerase. Cancer Res 59:5917–5921PubMedGoogle Scholar
  115. 115.
    Epel ES, Lin J, Wilhelm FH et al (2006) Cell aging in relation to stress arousal and cardiovascular disease risk factors. PNEC 31:277–287Google Scholar
  116. 116.
    Ogami M, Ikura Y, Ohsawa M et al (2004) Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol 24:546–550PubMedGoogle Scholar
  117. 117.
    Okuda K, Khan MY, Skurnick J et al (2000) Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 152:391–398PubMedGoogle Scholar
  118. 118.
    Matthews C, Gorenne I, Scott S et al (2006) Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 99:156–164PubMedGoogle Scholar
  119. 119.
    Chimenti C, Kajstura J, Torella D et al (2003) Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ Res 93:604–613PubMedGoogle Scholar
  120. 120.
    Davies MJ, Woolf N, Rowles PM et al (1988) Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 60:459–464PubMedGoogle Scholar
  121. 121.
    Minamino T, Miyauchi H, Yoshida T et al (2002) Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105:1541–1544PubMedGoogle Scholar
  122. 122.
    Oh H, Wang SC, Prahash A et al (2003) Telomere attrition and Chk2 activation in human heart failure. Proc Natl Acad Sci USA 100:5378–5383PubMedGoogle Scholar
  123. 123.
    Leri A, Franco S, Zacheo A et al (2003) Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J 22:131–139PubMedGoogle Scholar
  124. 124.
    Dai Q, Escobar GP, Hakala KW et al (2008) The left ventricle proteome differentiates middle-aged and old left ventricles in mice. J Proteome Res 7:756–765PubMedGoogle Scholar
  125. 125.
    Njajou OT, Hsueh WC, Blackburn EH, for the Health ABC Study et al (2009) Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. J Gerontol A Biol Sci Med Sci 64A:860–864Google Scholar
  126. 126.
    Kerber RA, O’Brien E, Cawthorn RM (2009) Gene expression profiles associated with aging and mortality in humans. Aging Cell 8:239–250PubMedGoogle Scholar
  127. 127.
    Jazwinski M, Kim S, Dai J et al (2010) HRAS1 and LASS1 with APOE are associated with human longevity and healthy aging. Aging Cell 9:698–708PubMedGoogle Scholar
  128. 128.
    Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/Non-ST-elevation myocardial infarction). J Am Coll Cardiol 50:652–726Google Scholar
  129. 129.
    Pearson TA, Blair SN, Daniels SR et al (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388–391PubMedGoogle Scholar
  130. 130.
    Smith SC, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47:2130–2139PubMedGoogle Scholar
  131. 131.
    Graham I, Atar D, Borch-Johnsen K for the European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 28:2375–2414Google Scholar
  132. 132.
    Schocken DD, Benjamin EJ, Fonarow GC et al (2008) Prevention of heart failure. A scientific statement from the American Heart Association Councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117:2544–2565PubMedGoogle Scholar
  133. 133.
    Fonarow GC, Yancy CW, Hernandez AF et al (2011) Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 161:1024–1030PubMedGoogle Scholar
  134. 134.
    Forman DE, Rich MW, Alexander K et al (2011) Cardiac care for older adults. Time for a paradigm. J Am Coll Cardiol 57:1801–1810PubMedGoogle Scholar
  135. 135.
    Kostis JB, Davis BR, Cutler J et al (1997) Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278:212–216PubMedGoogle Scholar
  136. 136.
    Staessen JA, Fagard R, Thijs L et al (1997) Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757–764PubMedGoogle Scholar
  137. 137.
    Gueyffier F, Bulpitt C, Boissel JP, for the INDIANA Group et al (1999) Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet 353:793–796PubMedGoogle Scholar
  138. 138.
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. New Engl J Med 365:2002–2012PubMedGoogle Scholar
  139. 139.
    Svetkey LP, Erlinger TP, Vollmer WM et al (2005) Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. J Hum Hypertens 19:21–31PubMedGoogle Scholar
  140. 140.
    Weiss EP, Fontana L (2011) Caloric restriction: powerful protection for the aging heart and vasculature. Am J Physiol Heart Circ Physiol 301:H1205–H1219PubMedGoogle Scholar
  141. 141.
    Willcox BJ, Willcox DC, Todoriki H et al (2007) Caloric restriction, the traditional Okinawan diet, and healthy aging: the diet of the world’s longest-lived people and its potential impact on morbidity and life span. Ann N Y Acad Sci 1114:434–455PubMedGoogle Scholar
  142. 142.
    Lenfant C (2002) Reflections on hypertension control rates. A message from the Director of the National Heart, Lung, and Blood Institute. Arch Int Med 162:131–132Google Scholar
  143. 143.
    Onysko J, Maxwell C, Eliasziw M et al (2006) Large increases in hypertension diagnosis and treatment in Canada after a healthcare professional education program. Hypertension 48:853–860PubMedGoogle Scholar
  144. 144.
    Tu K, Campbell NRC, Duong-Hua M, McAlister FA (2005) Hypertension management in the elderly has improved. Ontario prescribing trends, 1994 to 2002. Hypertension 45:1113–1118PubMedGoogle Scholar
  145. 145.
    Andersson OK, Almgren T, Persson B et al (1998) Survival in treated hypertension: follow-up study after two decades. Br Med J 317:167–171Google Scholar
  146. 146.
    Danaei G, Finucane MM, Singh GM, for the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure) et al (2011) National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 377:568–577PubMedGoogle Scholar
  147. 147.
    Kaul P, McAlister FA, Ezekowitz JA, Grover VK, Quan H (2011) Ethnic differences in 1-year mortality among patients hospitalized with heart failure. Heart 97:1048–1053PubMedGoogle Scholar
  148. 148.
    Bleich SN, Herring BJ, Flagg DD et al (2011) Reduction in purchases of sugar-sweetened beverages among low-income black adolescents after exposure to caloric information. Am J Public Health. doi: 10.2105/AJPH.2011.300350

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Medicine, 2C2 Walter MacKenzie Health Sciences CentreUniversity of Alberta and HospitalsEdmontonCanada

Personalised recommendations